Byondis B.V. appointed Timo K. van den Berg, Ph.D., as senior director, Immuno-Oncology (IO) Research and Development. Van den Berg assumes this role on September 1, operating out of Byondis’ headquarters in Nijmegen, the Netherlands.

Lisa Stockman Mauriello has passed from her battle with ALS.  As a loving wife and proud mother of three boys who all just graduated this year, it was with great elation that Lisa was able to personally witness these milestones. This was her primary goal. As a professional committed to helping people advocate for better healthcare, getting access to a medicine designed to give people like her more time with their families was another goal.

Medicines360, a global nonprofit women’s health pharmaceutical organization, appointed Tina Raine-Bennett, MD, MPH, FACOG, as CEO, following a broad national search. With more than 30 years of experience, Dr. Raine-Bennett has an extensive career of expanding research into women’s health and translating that research into clinical practice to improve health outcomes for women.

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co. Ltd., appointed Andree Amelsberg, M.D., MBA, as VP U.S. Medical Affairs, Oncology Business Group.

David Fontana, Ph.D., has become chief business and strategy officer of Umoja Biopharma, a leading oncology company leveraging its proprietary, integrated technologies to reprogram immune cells directly in the human body to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies.

Healthcare and molecular diagnostics veteran and former Abbott executive Mark Szewczyk has become chief commercial officer of Strata Oncology Inc., a precision oncology company advancing molecular indications for cancer therapies.

Tavanta Therapeutics, a specialty pharmaceutical company, has several new additions to its executive and senior leadership teams with the appointment of Andreas Maetzel, M.D., PhD as chief medical officer and the promotion of Elizabeth Manning Duus, Ph.D. to VP of clinical development.

Convergent Therapeutics, a clinical-stage pharmaceutical company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers, picked Philip Kantoff, M.D., as CEO.

Transine Therapeutics, a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP platform technology, appointed Jan Thirkettle, Ph.D. as CEO.

Viracta Therapeutics Inc., a precision oncology company targeting virus-associated malignancies, appointed Ayman El-Guindy, Ph.D., as chief scientific officer.